GSK has announced positive headline interim analysis outcomes from a Phase III trial, which is evaluating Blenrep (belantamab ...

In a move to safeguard its dominant position in cancer treatments, Merck agreed to license a drug from a Chinese company ...

On Thursday, GSK plc (NYSE:GSK) released headline results from a planned interim analysis of the DREAMM-7 head-to-head phase ...

GSK Plc said its blood cancer drug significantly reduced the risk of death when combined with another cancer treatment, ...

UK drugmaker GSK might be trading lower following Thursday’s nomination of vaccine sceptic Robert F Kennedy Jr as the USA’s ...

UK pharma group posts ‘statistically significant’ trial results for treatment combined with Blenrep pulled in 2022 ...

GSK plc (GSK, GSK.L), on Thursday, announced positive headline results from a planned interim analysis of the DREAMM-7 head-to-head ...

GSK reported positive results from its phase three ‘DREAMM-7’ trial on Thursday, highlighting a significant overall survival ...

LONDON, UK I 14, 2024 I GSK plc (LSE/NYSE: GSK) today announced positive headline results from a planned interim analysis of the DREAMM-7 ...

GSK (GSK) announced positive headline results from a planned interim analysis of the DREAMM-7 head-to-head phase III trial evaluating Blenrep ...

The trial met its primary endpoint of progression-free survival (PFS) and showed that belantamab mafodotin when combined with bortezomib plus dexamethasone (BorDex), significantly extended the ...

The DREAMM-7 trial showed Blenrep with BorDex lowered death risk in relapsed/refractory multiple myeloma vs. standard treatment. A phase 3 study in newly diagnosed transplant-ineligible multiple ...